Charles River Laboratories presents with optimistic growth expectations that seem a stretch given the business's current performance. See why CRL stock is a Hold.

Charles River has been riding rough waters in 2024, and as the CRO’s CEO predicted, the third quarter proved no exception. | ...

Farther Finance Advisors LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free ...

One of Massachusetts' major life science companies, Charles River Laboratories Inc., has revealed new details on its ongoing cost-savings initiatives, stating in an earnings call that it’s “already ...

Charles River Laboratories International Inc (NYSE:CRL) reported third-quarter 2024 revenue of $1.01 billion on Wednesday, a ...

Charles River Laboratories, a Wilmington, Mass., pharma services giant, is closing a Skokie office that will result in the ...

Charles River Laboratories Intl ( (CRL)) has released its Q3 earnings. Here is a breakdown of the information Charles River Laboratories Intl presented to its investors. Charles River Laboratories ...

Charles River Laboratories International, Inc. (CRL) updated financial guidance for 2024. Revenue and non-GAAP ...

Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a ...